Randomised trial of homocysteine lowering treatment of depression in later life (B-VITAge)

晚年降低同型半胱氨酸治疗抑郁症的随机试验 (B-VITAge)

• 批准号: nhmrc : 572594
• 负责人: A/Pr Kieran Mccaul
• 金额: $ 51.71万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-trial-homocysteine-b-vitage/98457
• 关键词: Randomised; trial; homocysteine; lowering; treatment

The causes of depression in later life are varied and complex, but available evidence suggests that cardiovascular disease plays an important role. High homocysteine (a robust risk factor for myocardial infarction and strokes) accounts for about 20% of all cases of depression in older age. We have previously shown that treatment with vitamins B12, B6 and folate reduces homocysteine. We propose to run a trial to test if lowering homocysteine decreases the severity and prevalence of depression.

导致晚年抑郁的原因是多种多样和复杂的，但现有证据表明，心血管疾病起着重要作用。高同型半胱氨酸(心肌梗死和中风的重要危险因素)约占所有老年抑郁症病例的20%。我们之前已经证明，用维生素B12、B6和叶酸治疗可以降低同型半胱氨酸。我们建议进行一项试验，以测试降低同型半胱氨酸是否会降低抑郁症的严重程度和患病率。